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Only recently have we begun to appreciate the importance and complexity of the
non-coding genome, owing in some part to truly significant advances in genomic
technology such as RNA sequencing and genome-wide profiling studies. Previously
thought to be non-functional transcriptional “noise,” non-coding RNAs (ncRNAs) are
now known to play important roles in many diverse biological pathways, not least in
vascular disease. While microRNAs (miRNA) are known to regulate protein-coding gene
expression principally through mRNA degradation, long non-coding RNAs (lncRNAs)
can activate and repress genes by a variety of mechanisms at both transcriptional and
translational levels. These versatile molecules, with complex secondary structures, may
interact with chromatin, proteins, and other RNA to form complexes with an array of
functional consequences. A body of emerging evidence indicates that both classes
of ncRNAs regulate multiple physiological and pathological processes in vascular
physiology and disease. While dozens of miRNAs are now implicated and described
in relative mechanistic depth, relatively fewer lncRNAs are well described. However,
notable examples include ANRIL, SMILR, and SENCR in vascular smooth muscle cells;
MALAT1 and GATA-6S in endothelial cells; and mitochondrial lncRNA LIPCAR as a
powerful biomarker. Due to such ubiquitous involvement in pathology and well-known
biogenesis and functional genetics, novel miRNA-based therapies and delivery methods
are now in development, including some early stage clinical trials. Although lncRNAs
may hold similar potential, much more needs to be understood about their relatively
complex molecular behaviours before realistic translation into novel therapies. Here, we
review the current understanding of the mechanism and function of ncRNA, focusing
on miRNAs and lncRNAs in vascular disease and atherosclerosis. We discuss existing
therapies and current delivery methods, emphasising the importance of miRNAs and
lncRNAs as effectors and biomarkers in vascular pathology.
Keywords: vascular disease, atherosclerosis, ncRNA, microRNA, lncRNA
INTRODUCTION
Vascular disease in its various forms remains a global health epidemic, despite decades of medical
and scientific endeavour to prevent it. Cardiovascular disease alone accounts for over 17 million
deaths each year, more than double what is attributable to cancer (Libby et al., 2016), and the
prevalence is only expected to rise (World Health Organization [WHO], 2017). Although major
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advances in the fields of cardiothoracic and vascular surgery
and percutaneous coronary intervention continue to improve
outcomes in patients who have already suffered cardiovascular
events, the key battle lies upstream in prevention. Strategies
to address risk factors, such as aggressive lipid-lowering, anti-
hypertensive, and anti-platelet therapies, have conferred some
benefit, but vascular disease rates still continue to rise (Bhatnagar
et al., 2016). Novel approaches to prevent onset and reduce
progression of vascular disease are desperately needed, but
progress is slow, and molecular mechanisms underpinning the
pathology remain poorly understood.
Atherosclerosis is the principal driver of cardiovascular
disease world-wide. It progresses over decades in the arterial
walls of susceptible individuals, in response to numerous well-
known risk factors, including inflammation and high circulating
cholesterol. The clinical effect of atherosclerosis varies widely
dependent on site, severity, and co-morbidity, and can range
from completely asymptomatic to clinically catastrophic in the
case of myocardial infarction (MI), stroke, and the acutely
ischaemic limb. In its early stages, atherosclerosis is sub-clinical
with endothelial dysfunction, intimal thickening, and plaque
formation occurring silently and insidiously, only becoming
clinically apparent when the plaque becomes large enough
to impinge on luminal blood flow or becomes unstable and
ruptures. In the coronary arteries, luminal stenosis results in
angina, manifest most commonly as chest pain on exertion,
and the equivalent in the peripheral vasculature, “intermittent
claudication,” can be completely disabling to those affected.
These chronic diseases, while not in themselves immediately life-
threatening, reduce quality of life and consume large amounts
of healthcare resources annually. Other sites of atherosclerosis
result in chronic kidney disease and hypertension, cognitive
impairment in cerebrovascular disease, and abdominal angina in
mesenteric disease.
Besides lifestyle interventions, attempts at managing
atherosclerosis have to date largely focused around the now
well-accepted dogma that high levels of circulating lipid lead to
accumulation of an expanding lipid-rich necrotic core in the sub-
intimal space of the arterial wall forming predominantly in areas
of low shear stress and endothelial dysfunction. Consequently,
lipid lowering strategies have predominated with no less than
seven different available statins, other drugs like ezetimibe,
fibrates, and most recently the development of monoclonal
antibodies against the PCSK9 receptor, such as evolocumab
(Sabatine et al., 2017) and alirocumab (Schwartz et al., 2014).
However, despite initially impressive results in the statin trials,
some now doubt their efficacy in primary prevention, and
staggering levels of LDL reduction as in the FOURIER trial
(Sabatine et al., 2017) do not seem to translate into dramatically
improved clinical outcomes. This suggests that lipid lowering
may not be the only mechanism of action at play (Sabatine et al.,
2017). The anti-inflammatory effect of statin drugs may be a
major factor, and new drugs targeted at reducing inflammation
such as canakinumab look promising. In the recently published
CANTOS trial, canakinumab which targets interleukin-1β
reduced the relative risk of MI in ischaemic heart disease patients
by 16%, without affecting lipid levels (Ridker et al., 2017).
In the search for new therapeutically exploitable pathways,
much is now known about endothelial cell (EC), smooth muscle
cell (SMC), adventitial cell, and immune cell behaviour in
atherosclerosis and vascular biology. The plaque is a complex
environment though, and mechanistic unravelling has long been
in process with notable recent additions, such as adventitial-
derived mesenchymal stem cell (MSC)-like GLI1+ cells shown to
modulate calcification in murine models (Kramann et al., 2016).
EC dysfunction is the earliest known detectable abnormality in
plaque formation, occurring at damage prone sites, such as vessel
bifurcations. ECs entrap circulating monocytes and lipoproteins
and facilitate their permeation into the sub-endothelial space
(Ross and Glomset, 1976; Gimbrone and García-Cardeña, 2016).
SMCs then proliferate and migrate into the intima in response
to secreted chemokines and growth factors, synthesising extra-
cellular matrix and sometimes undergoing phenotypic switch to
macrophage-like cells, upregulating inflammation. The recruited
monocytes therein become phagocytic and ingest the modified
lipoproteins until they are over-laden with lipid (foam cells),
and contribute to the accumulating necrotic core by undergoing
apoptosis and necrosis (Ley et al., 2011; Moore et al., 2013).
Although these pathways are now well investigated, there are
still novel angles to interrogate, and a wealth of protein coding
gene interactions still to explore. New genomic techniques such as
single cell RNA sequencing (RNA-Seq) in atherosclerotic plaque
promise to provide deeper insight in this respect (Tang et al.,
2009; Wills et al., 2013; Cochain et al., 2018) and small interfering
RNA (siRNA) therapies like inclisiran, which targets PCSK9
mRNA hold real promise (Ray et al., 2017).
This review focuses on another such avenue in the form of
non-coding RNA (ncRNA). The non-coding genome represents
an exciting yet complex layer in human physiology and
pathology. Although some function had been previously ascribed
to ncRNAs as early as the 1950s (transfer RNA and ribosomal
RNA), its only in the last few decades upon the discovery
that approximately 98% of the human genome is non-protein-
coding (Mattick, 2001), that the potential biological significance
of ncRNA has been even partly appreciated (Taft et al., 2007).
MicroRNA (miRNA) is the best studied family of ncRNA,
known to regulate thousands of protein-coding genes through
messenger RNA (mRNA) degradation (Jonas and Izaurralde,
2015). MiRNAs are 20–25 nucleotides in length and form a
characteristic “hairpin” structure. They are inherent in multiple
pathologies, and due to their stability in plasma, miRNAs have
also been proposed as biomarkers of MI (Bostjancic et al.,
2010), cancers (Hayes et al., 2014), rheumatological, and other
diseases. In terms of therapies, clinical trials are currently ongoing
to determine the efficacy and safety of “antimiRs” in diseases
such as cancer, hepatitis (Christopher et al., 2016), and other
conditions (see later). Long non-coding RNAs (lncRNAs) are
much less well characterised to date, but their importance in
gene expression is increasingly being recognised. In contrast
to miRNAs, lncRNAs are much longer at >200 nucleotides,
with more complex secondary structures. They may act both to
activate and to repress genes, exerting their effects by a variety
of mechanisms at both transcriptional and translational levels
(Mercer et al., 2009; Ponting et al., 2009). Evidence is limited
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but growing, and lncRNAs appear to be critical regulators of
many processes inherent to atherosclerosis, including endothelial
dysfunction, SMC behaviour, immune response, and glucose and
lipid metabolism. In this review, we intend to discuss ncRNA
biology and mechanisms, new and existing evidence for ncRNA
in vascular disease, and the potential for delivery of novel ncRNA
therapies in human vascular disease.
NON-CODING RNA BIOSYNTHESIS AND
MECHANISM OF ACTION
Since their discovery in 1993 in Caenorhabditis elegans (Lee
et al., 1993), miRNAs have now taken up an important niche
in genomics with almost 2000 known sequences in the human
genome. Usually, transcription of intronic miRNA is regulated by
the same promoter as the host gene. However, some miRNAs, are
shown to have multiple transcription start sites (Ozsolak et al.,
2008) and may be transcribed by a promoter distant from the
gene they occupy (Monteys et al., 2010). MiRNA transcription
is controlled by RNA polymerase II and RNA Pol II-related
transcription factors (Lee et al., 2004). The first product in the
process is a primary miRNA (pri-miRNA) molecule, with a
characteristic stem–loop structure, and lengths reaching up to
1 kilobase (kb). The next product in the sequence is a smaller
precursor miRNA (pre-miRNA) molecule, which is generated
by RNase III enzyme Drosha that cleaves the stem-loop of pri-
miRNA (Lee et al., 2003). The small, hairpin-shaped pre-miRNA
is then transported into the cytoplasm by exportin 5, where
the Dicer enzyme further processes it to generate a double-
stranded molecule, ready for assembly with the Argonaute
(Ago) protein (Bohnsack et al., 2004; Lund et al., 2004). The
final product in the miRNA biogenesis pathway is formation
of the RNA-induced silencing complex (RISC), consisting of
a mature, single-stranded miRNA molecule and Ago protein,
which induces post-transcriptional gene silencing (Huntzinger
and Izaurralde, 2011). Importantly, human miRNA lacks Ago
specificity and can bind to all Ago variants (Huntzinger and
Izaurralde, 2011). Recent evidence demonstrates that the Ago-
unbound miRNA strand isn’t always cleaved and both the 5p
and 3p strands are found in different sorts of tissues (Meijer
et al., 2014). The mature miRNA then facilitates gene silencing,
whereby mRNA degradation occurs in 66–90% of cases (Jonas
and Izaurralde, 2015) and mechanistically depends on mRNA
deadenylation, decapping, and cleavage by XRN1 nuclease
(Fabian and Sonenberg, 2012). On the contrary, miRNA-induced
repression of translation targets only 6–26% of genes (Eichhorn
et al., 2014) using primarily RNA helicases eIF4A and DDX6,
which repress cap-dependent translation (Jonas and Izaurralde,
2015).
A less simple but equally fascinating class of ncRNA is
lncRNA. Remarkably, lncRNAs outnumber not only miRNAs,
but also protein-coding genes. In fact, the number of lncRNAs
annotated continues to rise, due to recent advances and new
strategies in RNA sequencing and bioinformatic techniques,
and hence a much greater depth of sequencing (Clark et al.,
2015). Despite this, there is still no strict classification method,
and the most accurate definition of lncRNA at present is
“long RNA transcripts that do not encode proteins” (Quinn
and Chang, 2016). It is generally accepted that lncRNAs
should be longer than 200 nucleotides, separating them from
other shorter ncRNA molecules such as miRNAs, snoRNAs,
an piRNAs among others, but confusingly, some lncRNAs do
actually contain cryptic open-reading frames (ORFs) (Gascoigne
et al., 2012), and short open-reading frames (sORFs) encoding
micropeptides. These micropeptides can act independently
from large proteins, regulating essential biological processes
(Makarewich and Olson, 2017). For example, a skeletal muscle-
specific RNA, annotated as lncRNA LINC00948, encodes a
cryptic micropeptide “myoregulin” (MLN). MLN interacts with
sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA), preventing
Ca2+ uptake into the SR in skeletal muscle, and accordingly
MLN silencing improves Ca2+ handling (Anderson et al., 2015).
Similarly, it was reported that lncRNA LINC00961 also encodes
a polypeptide termed “small regulatory polypeptide of amino
acid response” (SPAR). Mechanistically, SPAR prevents mTORC1
activation via interaction with lysosomal v-ATPase while SPAR
deletion induces mTORC1 leading to muscle regeneration
(Matsumoto et al., 2016). Given these clear mechanistic roles
for encoded micropeptides, one might consider then that the
parent lncRNA transcripts are in fact “misannotated.” How can
a transcript that is experimentally proven to contain genetic
code for a protein be referred to as “non-coding”? Nomenclature
naturally evolves with new knowledge over time, and perhaps this
will change. Clearly though there are differences between a simple
mRNA which has one function only, to produce a peptide, and
the complex lncRNA molecule, with its myriad of interactions
and functions, which remain largely undiscovered.
Within the class of lncRNA, there are different sub-classes
of lncRNAs which include long intervening/intergenic ncRNAs
(lincRNAs), promoter upstream transcripts (PROMPTs),
enhancer RNAs (eRNAs), and natural antisense transcripts
(NATs). These are transcribed from intergenic and promoter
upstream regions, enhancers, and reverse strand of protein-
coding genes, respectively (Wu et al., 2017). Interestingly,
lncRNAs do not require polyadenylation to be functional and
upon transcription a significant proportion of lncRNA remains
non-polyadenylated. In fact, many lncRNAs are bi-morphic
and can exist in both polyadenylated and non-polyadenylated
states (Hangauer et al., 2013). Furthermore, lncRNAs can
exist in different forms and structures: some lncRNAs are
capped by snoRNAs at 5′ (Wu et al., 2016) or both ends (Yin
et al., 2012); others can occur in a circular form as circular
intronic RNAs (ciRNAs) and circular RNA from back-splicing
of exons (circRNAs) (Memczak et al., 2013; Zhang et al., 2013;
Zhang X. O. et al., 2014). ANRIL (discussed in more detail later)
is the most well-known ncRNA that can take a circular form.
Currently considered to be a form of ncRNA, these transcripts
exist in loops with a bond between the 3′- and 5′-ends. Much like
other lncRNA, they are thought to regulate gene transcription
and expression, acting as sponges for miRNA, and are extremely
abundant in the circulation.
Its now accepted that lncRNAs can modulate gene expression
on transcriptional, post-transcriptional, and translational levels.
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The function of a specific lncRNA depends much on its
cellular localization and context of the cell (i.e., basal/stressed).
In particular, nuclear lncRNAs mainly act on transcription,
while cytoplasmic lncRNAs modulate expression of gene
post-transcriptionally. In the nucleus, lncRNAs regulate the
epigenome, facilitate transcriptional control, and participate in
alternative splicing (Zhang K. et al., 2014). A good example of
lncRNA-mediated epigenetic control is ANRIL, which facilitates
the recruitment of the chromatin-modifying complex PRC2
and promotes silencing of p15INK4B tumour suppressor gene
(Kotake et al., 2010). Interestingly, after the discovery of eRNAs
(Kim et al., 2010), it has been further suggested that eRNAs
are able to modulate chromatin and facilitate its assembly
(Mousavi et al., 2013) and interact directly with DNA structure
to guide the enhancer to its promoter (Li et al., 2013). A similar
type of lncRNA, termed activating ncRNAs (ncRNA-as), can
also regulate transcription and are expressed from independent
genes (Orom et al., 2010). Further, lncRNAs modulate different
aspects of transcriptional control ranging from modulating the
expression of transcription factors, such as ncRNA-a7 (Orom
et al., 2010) and OCT4 pseudogene 5 (Bai et al., 2015), to
acting as co-activators and repressors independently, such as
Alu RNA inhibiting RNA polymerase Pol II directly (Mariner
et al., 2008). MALAT1 is an example of lncRNA modulation
of alternative splicing. Specifically, MALAT1 is enriched in
nuclear speckles and upon interaction with SR splicing factors
promotes alternative splicing (Tripathi et al., 2010). Within
the cytoplasm of a cell, lncRNAs can stabilise or lead to
mRNA decay and promote/inhibit translation. They can also
act as miRNA precursors or sponges, mimicking mRNA for
miRNA binding (Zhang K. et al., 2014). In the main lncRNA-
induced mRNA degradation occurs via Staufen1 (STAU1)-
mediated mRNA decay (SMD), where STAU1 binds to the
pairing of mRNA 3′-UTR sequences with lncRNA due to
complementary Alu elements (Park and Maquat, 2013). BACE1-
AS, a natural antisense lncRNA forms a bond with mRNA of
BACE1 and protects it from miR-485-5p-induced degradation
by masking the miRNA-binding site (Faghihi et al., 2010).
LncRNA such as Uchl1-AS can recruit ribosomes to Uchl1
mRNA and thus facilitate protein translation (Carrieri et al.,
2012). An interesting subset of lncRNAs termed translational
regulatory lncRNA (treRNA) can even repress translation.
TreRNA facilitates the assembly of a new ribonucleoprotein
(RNP) complex, which interacts with translation initiation
factor eIF4G1 resulting in translational repression of E-cadherin
(Gumireddy et al., 2013). Further, a well-studied lncRNA in
cancers, H19, has been recently demonstrated to be a precursor
for miR-675, which targets a tumour suppressor RB (Tsang
et al., 2010). H19 is considered to be an effectual molecule
itself, rather than just the primary transcript giving rise to
miR-675. In the setting of keratinocyte differentiation H19
acts as a sponge to miR-130b-3p, its target (Li et al., 2017;
Figure 1). Finally, it has been reported that circRNA CDR1-as
contains 63 binding sites for miR-7 and can act a “sponge” or
decoy for miR-7, thus reactivating the expression of its target
genes in neuronal tissues (Hansen et al., 2013; Memczak et al.,
2013).
FIGURE 1 | lncRNA H19 functions. This lncRNA acts both as a primary
transcript giving rise to miR-675, and also as a sponge to miR-130b-3p.
Overall, it is clear that small ncRNAs such as miRNAs and
different subsets of lncRNAs form complex molecular networks
within the cell, where both classes interact closely to regulate vital
cellular processes.
NON-CODING RNA IN VASCULAR
DISEASE
Discovery of novel ncRNAs in disease-specific context continues
to increase, largely due to the widespread application of
high-throughput gene expression arrays and development of
next-generation RNA sequencing. By far the most studied
field in this area is cancer, but already a significant number
of miRNAs are implicated in vascular disease and biology,
and although much less studied, several lncRNAs have been
discovered and are currently being investigated. Development,
cellular differentiation, and commitment are a logical starting
point to identify novel RNA candidates, and evidence of EC
growth and phenotype regulation in the case of MALAT1
increases the likelihood of an important function in pathology
for this lncRNA. The scope of this review, however, focuses
on ncRNAs in pathology. Here we describe some of the most
important discoveries to date, adding weight to the proposition
that miRNA and lncRNA transcripts represent worthwhile
and plausible targets for novel gene therapies in vascular
disease (see Table 1 for summary of key ncRNA in vascular
diseases).
MiRNAs
There is a large body of evidence demonstrating miRNA
involvement in many of the pathological processes that occur in
vascular disease, and atherosclerosis. Hundreds of miRNAs are
now reported as key regulators of lipid handling, inflammation,
and cellular behaviours, such as SMC and EC proliferation,
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TABLE 1 | Non-coding RNA in vascular disease.
Type Vascular examples Biological context Reference
miRNA miR-21 Biomarker of coronary artery disease,
upregulated in vein grafts
(Raitoharju et al., 2011; McDonald et al., 2013; Han et al., 2015)
miR-126 Promotes EC proliferation,
atheroprotective
(Wang et al., 2008; Schober et al., 2014)
miR-92a Endothelial inflammation, atherogenic (Loyer et al., 2014)
miR-33a/b Inhibits ABCA1 translation, atherogenic (Rayner et al., 2010; Horie et al., 2012)
miR-143/145 Complex interaction in atherosclerosis
and pulmonary hypertension:
upregulated in human unstable carotid
plaque, knockout blocks pulmonary
hypertension in murine model
(Cipollone et al., 2011; Deng et al., 2015)
miR-221/222 Dysregulated in acute plaque (Cipollone et al., 2011; Maitrias et al., 2015)
miR-1 Biomarkers for MI (Wang et al., 2010; McManus and Ambros, 2011)
miR-133a
miR-499
miR-208a
miR-192 Predictive of heart failure post-MI (Matsumoto et al., 2013)
miR-194
miR-34a
lncRNA ANRIL Transcribed from 9p21 locus,
associated with pathogenic changes in
atherosclerotic plaques
(Holdt et al., 2010)
MIAT Biomarkers for MI (Ishii et al., 2006; Vausort et al., 2014; Zangrando et al., 2014)
MIRT1/2
HIF1-AS2
KCNQ1OT1
SENCR Downregulated in human critical limb
ischaemia, and in premature coronary
artery disease
(Boulberdaa et al., 2016)
SMILR Induces SMC proliferation, upregulated
in human carotid plaques
(Ballantyne et al., 2016)
meXis Improves cholesterol efflux,
atheroprotective
(Sallam et al., 2018)
MALAT1 Downregulated in plaque, endothelial
phenotypic switch
(Arslan et al., 2017)
LIPCAR Predictive of heart failure post-MI (Kumarswamy et al., 2014)
migration, and phenotypic switch. Translation of these important
mechanistic findings into novel therapies in humans involves
a long and expensive process, and the vast majority of
mechanistic investigation is undertaken pre-clinically, in vitro,
and in animal models. Human experimental evidence usually
amounts to correlative findings in excised tissue samples, such
as carotid plaque, or in readily available plasma or cellular
blood components like peripheral blood mononuclear cells
(PBMCs).
As a readily accessible source of human tissue, carotid
plaque profiling has led to discovery and validation of several
dysregulated ncRNAs in this way. MiR-21 for example is
an important miRNA, which was found to be increased
more than sevenfold in human peripheral arteries with severe
atherosclerotic disease compared with controls. MiR-21 was
further shown to be increased in the circulation of apoE knockout
mice and humans with coronary artery disease (Raitoharju et al.,
2011; Han et al., 2015). In clinical application, expression of miR-
21 was shown to rise after engraftment of veins into murine
and porcine models, and in cultured human saphenous vein
explants. Subsequent knockdown in ex vivo human saphenous
vein explants using anti-miRs was then >95% efficacious, and
neointima formation was attenuated (McDonald et al., 2013).
MiRNAs can be tissue and disease specific, but as in the case of
miR-21, some transcripts are enriched across multiple tissues, and
regulate multiple processes (Ludwig et al., 2016). While known
to be an important factor in fibrosis and neointima formation
in vascular disease as above, miR-21 is also thought to be part
of an inflammatory positive feedback loop in vascular ECs. It
promotes adherence of monocytes via activator protein AP-1,
as well as negatively regulating LPS-induced lipid accumulation
and inflammatory responses in macrophages by the TLR4–NF-κB
pathway (Feng et al., 2014). The well-expressed and widespread
miR-21 has in fact now been targeted in several other diseases
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too, including kidney disease, and cancer and trials of therapy are
well underway (Denby et al., 2014; Nedaeinia et al., 2017).
Endothelial cell dysfunction is a critical and probable
triggering event in vascular disease mediated at least in part
by disturbed laminar flow in predisposed locations such as
vessel bifurcations. MiR-126 is an EC-enriched miRNA (Wang
et al., 2008) and is critical for EC proliferative reserve in
such areas, effective by suppression of the Notch1 inhibitor
delta-like 1 homolog (Dlk1). When denuded, recovery of the
endothelial layer was compromised when miR-126-5p deficient,
and treatment with miR-126-5p could rescue proliferation and
thereafter protect against atherosclerosis, suggesting a possible
therapeutic angle for this miR (Schober et al., 2014). Investigating
the effect of blood flow on miR expression, pulsatile flow was
shown to increase expression of the well-studied miR-92a (while
laminar flow reduces it) (Wu et al., 2011; Fang and Davies, 2012)
via the regulation of Kruppel-like factor 2 (KLF2), which is a
positive regulator of nitric oxide synthesis. MiR-92a inhibition
then reduced endothelial inflammation, and hence plaque size
(Loyer et al., 2014). Clinical development of an “antagomir”
designed to inhibit miR-92a is now in process, and multiple other
animal models have demonstrated significant vascular benefit
in downregulating this important transcript. Roles have since
been defined beyond endothelial dysfunction too, in angiogenesis
and proliferation, translating into enhanced cardiac recovery and
cardiac protection (see later).
Lipid handing is also central to evolution of atherosclerotic
plaques and appears to be regulated by a number of different
miRNAs. The adenosine triphosphate-binding cassette (ABC)
transporter, ABCA1 specifically is subjected to complex miRNA
regulation, and ABCA1 is known to be critical to cholesterol
transport and high-density lipoprotein (HDL) biogenesis in
the liver (Rotllan et al., 2016). This is particularly important
because HDL is recognised as one of the few reliably validated
risk factors in atherosclerotic disease. There have been multiple
unsuccessful pharmacological attempts to increase HDL. Trials
using niacin and CEPTB inhibitors, such as torcetrapib, have
shown no benefit and in fact, the ILLUMINATE trial was
stopped early due an increase in all cause mortality in the
treatment group (Barter et al., 2007; Boden et al., 2011).
MiRNA manipulation may still be possible though, as we
know that ABCA1 translation is directly inhibited by miR-33
(Rayner et al., 2010) which results in attenuation of cholesterol
eﬄux, and when miR-33 is genetically deleted in atherogenic
murine models, plaque volume and lipid content are reduced
(Horie et al., 2012). Correspondingly, circulating HDL is
increased in miR-33 knockout mice, and reduced when it is
overexpressed. This has been further validated in non-human
primates, perhaps more reassuring of significance in humans,
particularly as the mouse locus does not encode miR-33b,
whereas in primates the local genomic profile is much more
similar (Rayner et al., 2011). MiR-33a and miR-33b remain
exciting targets in vascular prevention, but recent evidence
suggests that while loss of these miRNA may be beneficial in
terms of macrophage behaviour within the plaque (reduced size
and volume), full knockout actually results in obesity, insulin
resistance, and hyperlipidaemia overall, albeit in a mouse model
(Price et al., 2017). Obviously the environment is complex,
and the ABCA1 locus is regulated by a number of other
miRNAs, and interestingly a recently discovered lncRNA meXis
(Rottiers and Näär, 2012; Sun et al., 2012; Zhang M. et al., 2014;
Sallam et al., 2018) (described later).
In vascular SMCs, the miR-143/145 cluster is now a
well-recognised regulator of cell function. Generally, the
literature describes downregulation in the disease state, and an
improvement when replaced or over-expressed. For example, in
murine aortic constriction, miR-143/145 expression is reduced,
and knockout mice have abnormal arterial structures and
evidence of de-differentiation on histological analysis (Elia et al.,
2009). Further, the knock-out of miR-143/145 resulted in loss of
SMC contractility and favoured neointimal formation (Boettger
et al., 2009). Whereas in lentiviral overexpression of miR-145,
plaque appearances were overall improved with a reduction
in plaque size, and amelioration of features associated with
instability such as size of lipid core and thickness of fibrous cap
(Lovren et al., 2012). Findings in human samples then largely
corroborate the hypothesis that the cluster is downregulated in
disease, consistent in aortic aneurysm tissue versus control, and
in the PBMCs of hypertensive patients (Elia et al., 2009; Kontaraki
et al., 2014). It has been demonstrated that the process of actin
depolymerisation in mild aortic dilation leads to downregulation
of miR-143/145 regulated by myocardin-related transcription
factors (MRTFs) (Alajbegovic et al., 2017). However, another level
of complexity is suggested by conflicting evidence in apparent
upregulation in carotid artery plaques of patients with stroke
(Cipollone et al., 2011), and similarly higher expression in the
carotid plaques of patients with hypertension (Santovito et al.,
2013), and pulmonary artery SMCs of patients with pulmonary
hypertension (Caruso et al., 2012; Deng et al., 2015). Clearly
much is yet to be learned about their significance, and complex
interactions before precise therapeutic options are defined in this
case.
The miR-221/222 cluster is another important regulator
of vascular cell function in plaque rupture although it too
has a complicated, sometimes conflicting representation in
the literature. Prevention of plaque rupture is of course
an important aim of treatment in vascular disease, whether
carotid, coronary, or peripheral. The miR-221/222 cluster has
been implicated in this acute process, and while consistently
identified as a dysregulated miRNA in acute plaque (Cipollone
et al., 2011; Maitrias et al., 2015) was shown to have
apparently opposing effects dependent on cell type in VSMCs
and ECs (pro-proliferative/migratory in VSMCs, yet anti-
proliferative/migratory in ECs) (Liu et al., 2012). Critically, miR-
221/222 levels appear to reduce at the time of plaque rupture,
and then normalise around 2 weeks after the event (Bazan et al.,
2015). Precision targeting of this cluster in the plaque to prevent
fibrous cap degradation, hence, seems beneficial. However, the
widespread effects of manipulating circulating levels of miR-
221/222 need to be thoroughly studied, because this very well-
conserved miRNA appears to be enriched in patients with
diabetes (Coleman et al., 2013) and plays important roles in
various types of cancer, too (Song J. et al., 2017). As with any
ncRNA therapy targeted at a particular disease process in specific
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cells or tissues, the specificity of action is hence absolutely critical.
Similarly, in the development of an anti-miR to miR-21, off-target
effects of systemic dissemination were observed as expected,
including a rise in serum creatinine, but some success was had
with a drug-eluting stent (DES) delivery which reduced in-stent
restenosis, without off-target problems (Wang et al., 2015) (see
later).
LncRNAs
Increasingly, lncRNAs emanating from multiple sources are
shown to be implicated in cardiovascular disease. The lncRNA
anti-sense noncoding RNA in the INK4 locus (ANRIL) is
transcribed from the now well-known 9p21 locus, which has
been strongly implicated in vascular disease (Holdt et al., 2010;
Congrains et al., 2012; Cheng et al., 2017). It was initially
discovered through genome-wide association studies detecting
several polymorphisms, which were predictive of atherosclerosis
(Wellcome Trust Case Control Consortium, 2007; Samani et al.,
2007). Notably, important tumour suppressor genes CDKN2A
and CDKN2B are also found near this region, but are not
found to be dysregulated in atherosclerosis models and patients,
unlike ANRIL (Chen et al., 2014). ANRIL was one of the first
lncRNAs described in atherosclerosis, and multiple interactions
have now been demonstrated, although the full extent of its
regulation in vascular disease remains unclear. As is the case with
most lncRNAs, ANRIL is alternatively spliced, and expressed as
multiple “isoforms.” Ensembl currently reports 21 splice variants,
each of which may interact differently to the others. Further
adding to its complexity, ANRIL is found in multiple cell types
including SMCs, ECs, and inflammatory cells. Initially, ANRIL
appeared to be grossly associated with pathogenic changes;
reduced cell viability and proliferation in SMCs (Congrains et al.,
2012), upregulation of inflammation and apoptosis in ECs (Song
C.L. et al., 2017), and a consistent correlation with atherosclerotic
burden in human PBMCs and plaque samples (Holdt et al., 2010).
More recently though a circular variant has been characterised,
circANRIL, which seems to be atheroprotective in its behaviour;
by controlling ribosomal RNA biogenesis and modulating some
atherogenic processes in VSMCs and macrophages (Holdt et al.,
2016). Unless otherwise stated, ANRIL would hence usually refer
to the linear transcript (linANRIL). This alternatively structured
RNA from the same locus exemplifies the added layers of
complexity in lncRNA biology compared with smaller micro and
other ncRNAs.
Until now, in vitro work has led to limited characterisation
of some other vascular lncRNAs in relevant cell types, but
translation into definite therapeutic targets in humans requires
complex mechanistic unravelling, which in most cases is in the
early stages. LncRNAs identified in circulatory samples from
atherosclerosis patients, or from GWAS, may provide a starting
point for vascular targets, but confounding processes such as
myocardial injury and repair or the general upregulation of
inflammation are equally likely to account for these correlative
findings. Notable examples include MI-associated transcript
(MIAT) (Ishii et al., 2006), another transcript discovered by large
case–control genome association study in patients with MI, and
MI-related transcripts 1 and 2 (MIRT1, MIRT2) in a murine
MI model (Zangrando et al., 2014). While dysregulation in the
disease state is apparent, mechanistic work to show why this is
remains to be seen.
As with miRNAs, a certain insight has been achieved from
in vitro cellular models. Although cultured cell lines representing
one cell type are not truly analogous to the multicellular
in vivo environment, it is possible to investigate candidate novel
transcripts, and to identify at least if these are important in
cellular function in the first instance. In coronary artery SMCs,
the smooth muscle and EC-enriched migration/differentiation-
associated lncRNA (SENCR) is an example of a transcript
discovered by RNA sequencing, and functionally characterised
in relevant cell types. SENCR was shown to be anti-migratory in
SMCs, and subsequent RNA-Seq after SENCR knockdown then
demonstrated a reduced expression of myocardin and numerous
contractile genes, consistent with the observed phenotype (Bell
et al., 2014). Subsequently, lower levels of SENCR in human
critical limb ischemia and in the ECs of patients with premature
coronary artery disease were observed (Boulberdaa et al., 2016),
again supporting that hypothesis that SENCR is downregulated
in pathology. One might propose then that targeted delivery of
SENCR in areas of deficiency might then ameliorate maladaptive
SMC behaviours. Another vascular lncRNA, smooth-muscle-
induced lncRNA (SMILR), was investigated in a similar manner,
but in this case upregulation of SMILR was associated with
vascular SMC proliferation, and in human atherosclerotic plaque
SMILR is enriched. Mechanistic investigation showed that SMILR
may exert its effects by interaction with cis protein HAS2,
which codes for hyaluronic acid. HAS2 was also reduced on
SMILR knockdown, and the SMC phenotype was of reduced
proliferation (Ballantyne et al., 2016). Therapeutic targeting of
SMILR with in vivo locked nucleic acids (LNAs) might prove
useful in preventing neointima formation in clinical settings.
Aside from the cells which are inherent to the vascular wall,
inflammatory cells like monocytes and macrophages are the key
regulators of lipid handling within the plaque, and recently it was
shown that the lncRNA meXis is an amplifier of the ABCA1 gene,
via the sterol activated liver X receptors (LXRs). LXRs are sterol-
activated nuclear transcription factors, and may be important
in the pathology of atherosclerosis, as key regulators of genes
involved in cholesterol transport. MeXis interacts with and guides
promoter binding of the transcriptional coactivator DDX17, so
loss of the gene resulted in impaired cholesterol eﬄux, and
accelerated atherosclerosis in murine models. As discussed, any
novel target for improving cholesterol eﬄux (which is beneficial
in plaque disease) certainly warrants further investigation (Sallam
et al., 2018).
Utilising human samples excised at coronary endarterectomy
a recent study compared lncRNA expression from diseased left
anterior descending (LAD) artery plaque with inferior mammary
artery control tissue. This is a rarely performed procedure,
and coronary artery samples from live patients are not usually
readily available. The inferior mammary artery used as a control
here is preferentially used for LAD coronary artery bypass and
tends to be quite resistant to atherosclerosis with low failure
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rates (Etienne et al., 2013). Differential lncRNA expression was
observed in three of the five plaques chosen for analysis, with
upregulation of ANRIL and MIAT while metastasis-associated
lung adenocarcinoma transcript 1 (MALAT1) was downregulated
(Arslan et al., 2017). This reinforces the initial premise that these
lncRNAs which had been previously proposed as atherosclerosis-
related lncRNAs, and had been found in the circulation of
patients with acute MI (Vausort et al., 2014), are in fact
reproducibly found in human tissue.
MALAT1 briefly described above is frequently cited in vascular
disease and widely in multiple pathologies (primarily cancer) is
a very well-conserved and highly expressed lncRNA (Gutschner
et al., 2013). Having initially been demonstrated as a prognostic
marker in non-small cell lung cancer (Ji et al., 2003), MALAT1
appears to be also relevant in vascular disease, and was shown
to control phenotypic switch in ECs, as well as impair vessel
recovery in a hind-limb ischaemia model when knocked down
using in vivo GapmeRs (Liu et al., 2014; Michalik et al., 2014).
The use of in vivo GapmeRs to knock down chosen ncRNAs will
be discussed later.
NON-CODING RNA AS BIOMARKERS
Peripheral blood samples are easy to access, as are large-scale
array systems for identification of differentially regulated genes,
so it is unsurprising that there are now many miRNAs described
as biomarkers of various diseases. In addition, miRNAs are quite
well expressed in the circulation, and stable in stored samples of
blood and plasma, throughout freeze/thaw cycles, making them
reasonable to handle (Chen et al., 2008; Mitchell et al., 2008).
Examples in vascular disease include striated muscle-enriched
miRNAs such as miR-1, miR-133a, and miR-499, which were
upregulated in a population of acute MI patients and were highly
sensitive for MI by receiver operating characteristic (ROC) curve
analysis (Wang et al., 2010) compared with patients with no MI.
Similarly, miR-197 and miR-223 were shown to be predictive of
future cardiovascular death over a 4-year follow up in a large
sample of patients with documented coronary artery disease,
some with and some without acute infarction (Schulte et al.,
2015). These are two miRNAs which have been serially implicated
in this context, and in a different study were shown to predict
future cardiovascular events from baseline. This time there was
a negative correlation between circulating levels of miR-197
and miR-223, and another miRNA miR-126 was shown to be
positively correlated. More in depth investigation showed that
miR-223 and 197 were highly expressed in platelets, whereas
miR-126 was more EC enriched (Zampetaki et al., 2012). The
origin of circulating transcripts is usually difficult to ascribe, but
as the authors speculate in this case, it seems in-keeping with
previous knowledge that the lower levels of miR-197 and miR-223
may reflect platelet dysfunction, and the higher levels of miR-126
could be indicative of endothelial dysfunction.
In heart failure post-MI, miR-192, miR-194, and miR-34a
are predictive of heart failure up to 1 year, and correlate
with left ventricular dilatation on echocardiography (Matsumoto
et al., 2013). Centrally acquired samples from the coronary
circulation are potentially more valuable though, and in a
more intricate biomarker study the localisation of miRNA
release was characterised in a similar panel of candidates. Using
coronary catheters to access the aorta and coronary venous
sinus, simultaneous EDTA blood samples were taken from
patients with stable coronary disease, troponin positive acute
coronary syndrome (ACS), and normal controls. Not only were
miR-133a, miR-499, and miR-208a elevated in patients with
ACS, but a trans-coronary gradient was noted in miR-133
and miR-499, strongly suggestive of myocardial or coronary
release due to injury (McManus and Ambros, 2011). As well
as validating the novel biomarkers in ACS, this study suggests
that localised cardiac sampling may be preferable to peripheral
methods, especially in lowly expressed targets. Peripheral blood
sampling remains the easiest and most accessible route, however,
and caution must be exercised when undertaking PCR in
centrally acquired samples, because heparin which is frequently
used to anticoagulated cardiac patients undergoing cardiac
catheterisation is known to inhibit PCR downstream due to
binding of proteins required for the reaction (Beutler et al., 1990).
Although comparatively fewer lncRNAs are described as
biomarkers of vascular disease thus far, these versatile molecules
have been reliably detected in the circulation in cancer (Bolha
et al., 2017) and their tissue specificity like miRNA makes
them likely candidates. In a cohort of 414 patients with acute
MI, the expression levels of five known lncRNAs in circulating
cells were measured, demonstrating higher levels of hypoxia
inducible factor 1A antisense RNA 2 (HIF1A-AS2), KCNQ1OT1,
and MALAT1 compared with controls, while ANRIL went down.
In addition, four of the five were predictive of future left
ventricular systolic function. Similarly, long intergenic ncRNA
predicting cardiac remodelling (LIPCAR) is readily detectable in
human plasma and is uncharacteristically well expressed for a
lncRNA. In a global transcriptomic analysis of patients post-MI,
LIPCAR independently predicted cardiovascular death, despite
being initially lower expressed immediately after MI, levels
subsequently rose (Kumarswamy et al., 2014).
Already it is clear that many ncRNA species are deeply
involved in the pathology of vascular diseases. These manipulable
molecules represent feasible targets for therapeutic modification,
but also as diagnostic biomarkers or predictors of risk. It seems
unlikely that ncRNA could ever replace cardiac troponins in
the evaluation of sudden onset chest pain and diagnosis of MI,
which are tremendously well validated, but due to their potential
specificity to individual processes within the pathology, such as
plaque instability, they may still find a role (Chapman et al.,
2017).
NON-CODING RNA LIMITATIONS AS
BIOMARKERS
While ncRNA hence have the required specificity to pathology to
be suitable biomarkers, a current limitation is in their extraction
and quantification. Unlike highly abundant proteins such as
troponin, which can be easily measured using an ELISA assay
for example, RNA is more difficult to isolate in reasonable
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quantities and reproducibly so from acellular bodily fluids
such as plasma or serum. Very small amounts of RNA are
generally exported in extracellular vesicles, as in the case of
miRNA, and some likely escapes from damaged circulating or
vascular cells and may be bound to proteins. However, the
exact origins of circulating lncRNA in particular are not at
all understood, and the vast majority of RNA in the body is
intracellular. However, traditional methods, such as NanodropTM
spectrophotometry, fluorometric measurement using QbitTM,
and even automated electrophoresis with Agilent Bioanalyzer
which are commonplace for cellular RNA applications, are not
sensitive enough in realistically sized sample volumes of cell-
free bodily fluids. Not only does this hamper scientific study
and development, but inherent biases may also be introduced.
With the expected low expression of ncRNA molecules, cycle
threshold (CT) values on qPCR will be very high, towards the
upper limit of detection for the machinery, and become less
reliable. Of course, accuracy is always compromised throughout
the entire work stream when the absolute quantity is reduced.
Furthermore, in the discovery phase, the tendency to study
only the highest expressed of the ncRNA species leads to
neglect of the less well-expressed transcripts. Lower abundance
does not necessarily mean lower importance. As a result,
although multiple studies report differential expression of novel
lncRNA biomarkers in human plasma and serum, others
have found difficulty in replicating (Schlosser et al., 2016).
A noteable exception is LIPCAR, which is highly expressed and
consistently detectable in plasma samples (Kumarswamy et al.,
2014).
NON-CODING RNA THERAPEUTICS
AND DELIVERY METHODS
Here we discuss current knowledge on new and emerging
therapies using ncRNA technologies. Proposed methods of
delivery are shown in Figure 2.
MiRNA AS THERAPEUTIC AGENTS
In the large class of ncRNAs, miRNAs currently possess the
strongest therapeutic potential due to our greater knowledge of
them, clearer mode of action, and ability to regulate multiple
genes in multiple molecular pathways. Moreover, due to their
pleiotropic mechanism of action, a manipulation of a single
miRNA could potentially induce a therapeutic effect within
several cells and tissues. With re-emerging interest in RNAi
therapeutics (Zeliadt, 2014), it is possible that miRNA-based
therapies will progress further in the coming years.
Ultimately, efficacy depends on both modification of the RNA
molecule, and its vehicle for delivery. The two principle strategies
for miRNA therapeutics include overexpression of miRNA by
synthetic oligoribonucleotide (ORN) delivery or targeted miRNA
inhibition using single-stranded antisense oligonucleotides (anti-
miRs). In order to obtain better delivery efficiency, the ORNs
can be subjected to chemical modifications, such as 2′-O-
methoxyethyl (2′-MOE) substitutions and LNA bases, which
stabilise the ORNs (Hutvagner et al., 2004; Orom et al., 2006;
Elmen et al., 2008a). In particular, the 2′-MOE modification is
FIGURE 2 | Non-coding RNA therapy delivery – proposed delivery methods of ncRNA-based therapeutics in vascular disease. RNA therapeutics can be delivered to
the vascular system using vehicles such as viral vectors, nanoparticles, and pluronic gel; intravascular devices such as drug-eluting stents; or by direct injection.
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generally used to prevent degradation of ORN as well as to mask it
from the immune response, whereas LNA enhances the affinity of
miRNA and stabilises the ORN further (Davis et al., 2006; Henry
et al., 2011). The use of such modifications to improve expression
modulation of certain miRNA has been validated numerously in
the vascular disease setting, including examples such as delivery
of 2′-OMe-miR-21 to rat carotid artery (Ji et al., 2007), systemic
downregulation of miR-92a with LNA-anti-miR to induce re-
endothelialisation (Daniel et al., 2014) as well as intravenous
delivery of LNA-anti-miR-15b to reduce cardiac remodelling in
mice post-MI (Hullinger et al., 2012).
In addition to ORN modifications, efficient RNA delivery
vehicles are required to facilitate their uptake. There are several
studied and trialled thus far, as discussed below. The most
common delivery method to date is the use of lipid-based
nanocarriers, which package the RNA, allowing it to cross the
cellular membrane (Pirollo et al., 2008; Trang et al., 2011).
Notably, in a study carried out by Weber’s group it was shown
that miR-126-5p mimics packaged in this way were effectively
and efficiently transfected in vivo. The cargo was delivered
intravenously to high cholesterol diet mice, resulting in a
marginal decrease in atherosclerotic lesion formation, and an
increase in luminal EC proliferation. They reported in the same
study that using pluronic gel-based delivery was also effective,
in this case for local delivery of anti-miRs injected around the
mouse carotid artery (Schober et al., 2014). Pluronic gel can
be used internally or topically, and was also used effectively in
a recent study by Miscianinov et al., where miR-148b mimics
were topically administered to efficiently enhance angiogenesis
and wound healing in vivo. It was noted in this case, however,
that the delivery of anti-miR-148b within the pluronic gel had
impaired wound closure and induced EndMT in the wound
vasculature, possibly a result of the target manipulation more-so
than the mode of delivery (Miscianinov et al., 2018). Alternative
methods to package and deliver RNA-based therapies involve
polymer- and peptide-based systems, such as polylactic-co-
glycolic acid (PLGA) and polyamine-co-ester terpolymer (PACE)
nanoparticles. The latter are able to release the ORNs steadily
over time (Woodrow et al., 2009; Zhou et al., 2011). PLGA
was used in the vascular setting when an anti-miR to miR-92a
encapsulated by PLGA microspheres was delivered directly to pig
coronary arteries. MiR-92a expression was downregulated locally,
preventing left ventricular remodelling in a model of reperfused
MI (Bellera et al., 2014).
Of course, viral vectors such as adenovirus (AV) and adeno-
associated virus (AAV) are among the best known vehicles
for gene therapies due to their natural ability to infect, and
transfer genetic information. Viruses have been used to efficiently
deliver many different cargoes in vivo previously like the tissue
inhibitor of metalloproteinase-3 (TIMP3) in vein graft failure,
which reduced neointimal formation consistently (George et al.,
2000). The commonly used vector AAV has been equally well-
studied, and delivery of hsa-miR-590 and hsa-miR-199a pre-miRs
to the neonatal rat heart was shown to significantly reduce
infarct size and improve cardiac function post-MI (Eulalio et al.,
2012). Despite concerted efforts to optimise this process however,
viral delivery can be hampered by several drawbacks, namely
the triggering of immune response (especially in the case of
AV), off target effects, and the sometimes undesirable long-term
incorporation of the virus’s genes into those of the host.
Specificity of site of action hence represents one of the major
barriers to developing successful miRNA therapies, as in both
of the above classes of examples. However, some success has
been seen with attempts to deliver miRNA therapies locally. In
the vasculature in particular, drug eluting stents were already
widely used in percutaenous coronary intervention, releasing
anti-proliferative and immunosuppressive drugs to prevent re-
stenosis. In a similar approach, it was shown that delivery of LNA
anti-miR-21 by DES significantly attenuated in-stent restenosis
in the humanised rat myointimal hyperplasia model (Wang et al.,
2015). Photoactivatable antimiRs, which have photolabile cages
attached to the oligonucleotide structure are only activated by
light, therefore generating an inducible model (Zheng et al., 2011;
Connelly et al., 2012). This ensures that the miR treatment is
only efficiently released at the intended site. Clearly this is useful
in skin, but perhaps less so internally. Efficacy of a miR-92a
light-inducible compound was demonstrated in superficial mice
wounds, and was able to enhance proliferation and angiogenesis
(Lucas et al., 2017). Finally, incorporation of miRNA therapy
with a thioaptamer, specifically interacting with a chosen ligand,
E-selectin in this example, may be useful to ensure specificity.
The aptamer binds to the chosen molecule and guides the
miR therapy, miR-146a and miR-181b to inflamed endothelium,
reducing atherosclerosis in mice (Ma et al., 2016).
As there are currently no clinical trials focused on ncRNAs in
vascular disease, we will describe studies in liver and heart and
translational relevance for vascular disease. The most successful
example of miRNA-based therapeutics to date is anti-miR-122
compound for hepatitis C. It has been demonstrated in Jopling
et al. study that miR-122 is highly and specifically expressed in
human liver. Moreover, it has been shown that inhibition of
miR-122 was able to strongly decrease viral RNA of hepatitis C,
introducing the novel idea for a potential miR-122-modulating
therapy (Jopling et al., 2005). Since then a lot of work has
been done to achieve an efficient miR-122 inhibition method
in vivo, primarily using 2′-MOE-modified anti-miR (Krutzfeldt
et al., 2005; Esau et al., 2006). Furthermore, anti-miR-122 LNA
modification approach was efficient in downregulating miR-122
expression in mice, which was delivered intravenously (Elmen
et al., 2008b). Notably, preclinical trials on chimpanzees have
confirmed that LNA-anti-miR-122, now known as SPC3649 or
Miravirsen, leads to significant reduction in hepatitis C viral load
with no side-effects (Lanford et al., 2010). Currently, Miravirsen
is being developed by Santaris Pharma and since 2017 is in Phase
II clinical trials (Titze-de-Almeida et al., 2017).
In other translational studies, direct intra-cardiac injection of
miR-21, miR-1, and miR-24 reduced infarct size in mice, with
LAD ligation, at 24 h (Yin et al., 2009). The mice underwent
ischaemic preconditioning, forcing an altered miRNA expression
profile, with the hypothesis that these miRNA would be protective
in the case of infarct. The miRNAs were then extracted and
injected into the infarct model, resulting in an increase of eNOS,
HSF-1, and HSP70. Direct injection of miRNA seems to be
effective therefore in altering tissue expression of important
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mRNAs and proteins. In a mesenchymal stem cell vector, miR-
1 was overexpressed and injected into infarcted myocardium
again in a mouse model of infarct, resulting in enhanced cell
survival and improved cardiac function (Huang et al., 2013). In a
similar way but with a different mode of delivery, polyketal (PK3)
nanoparticles (a solid polymer) were used to deliver miRNA
mimics miR-106b, miR-148b, and miR-204 to macrophages in
mice hearts, all targeting Nox2 expression. Infarct size was
significantly reduced, and function improved (Yang et al., 2017).
The alternative approach of miRNA inhibition has also been
shown to be effective in the cardiovascular setting, and in some
cases may be technically easier to achieve. Anti-miRs can be
quickly designed and developed, and in vivo delivery of the
anti-miR-143 is protective in the development of pulmonary
arterial hypertension in mice (Deng et al., 2015). MiR-143-3p
is selectively upregulated in cell migration, and its modulation
significantly reduces cell migration and apoptosis.
Vein graft failure in surgical coronary artery bypass has been
a longstanding problem, and the setting for some significant
advances in ncRNA therapy. MiR-21 expression is elevated in
mice, porcine, and human ex vivo models of vein graft failure, and
localises to the SMC layers of the forming neointima in the failing
grafts. Delivery of anti-miR-21 to inhibit miR-21 was effective
to reduce expression and attenuate the pathological neointima
formation in a model of vein graft failure (McDonald et al.,
2013), and now further clinical investigation is needed before
this can be applied clinically. In a completely different disease
system its also been reported that inhibition of the same miR-21
using anti-miR treatment can prevent Alport syndrome in mice.
This disease which is characterised by glomerulonephritis and
progressive renal failure also results in sensorineural deafness in
the human form (Gomez et al., 2015). As a result of these findings,
‘Regulus Therapeutics’ are now carrying out a Phase II clinical
study (NCT02855268) of the safety and efficacy of RG-012 drug
(anti-miR-21) in the treatment of patients with Alport syndrome.
In the targeting of another miRNA, miR-92a, it was shown that
downregulation of miR-92a expression using 2′-O-methyl anti-
miR ORNs enhanced in vivo angiogenesis, neovascularisation as
well as enhanced post-MI recovery in mice (Bonauer et al., 2009).
This apparent pro-angiogenic and cardioprotective effect of anti-
miR-92a therapy was further investigated by the same group.
Specifically, they demonstrated that catheter-based delivery of
anti-miR-92a with LNA modification (LNA-92a) led to a decrease
in the infarct size in pig hearts and improved cardiac function
(Hinkel et al., 2013).
With the advances of CRISPR/Cas9 technology and the
ability to modify the genome at the base pair level, this
method has become a very attractive and promising approach
to generate both gain- and loss-of-function miRNA phenotypes.
Interestingly, an in vitro transfection of CRISPR/Cas9 vectors,
which contain sgRNAs, targeting the biogenesis processing sites
of miR-17, miR-200c, and miR-141, decrease the expression of
these miRNAs up to 96% (Chang et al., 2016), an impressive
knockdown. Moreover, subcutaneous injection of HT-29 cells
with CRISPR/Cas9-mediated miR-17 knockdown into nude mice
resulted in almost complete knockout of miR-17 expression in the
in vivo environment after 28 days (Chang et al., 2016). Despite
the clear benefits of the CRISPR/Cas9 approach in modulating
miRNAs in vivo, the usual obstacles, such as off-target effects
and lack of delivery vehicles with tissue specificity are yet to be
overcome.
LncRNA-BASED INTERVENTION
STRATEGIES
Given the fact that lncRNAs guide gene expression from start
of transcription to protein translation, this class of molecules
possess a promising therapeutic potential. The first study
involving modulation of lncRNA expression for therapeutic
purposes described the oncogenic lncRNA H19. In particular,
it has been reported that H19 is specifically expressed in over
30 tumours. Based on those findings, a plasmid expressing
diphtheria toxin under control of the H19 promoter (BC-819)
has been intratumoraly injected into bladder tumour leading to a
significant reduction in the tumour size in mice (Smaldone and
Davies, 2010). This led to intiation of phases I and II human
clinical trials, in which H19 promoter-based plasmid is used
to treat patients with different types of malignancies such as
bladder, pancreatic, and ovarian cancers (Smaldone and Davies,
2010). Recently reported results seem promising, including in the
treatment of early stage bladder cancer, BioCanCell report that
BC-819 treatment resulted in 54% of patients recurrence-free at
24 months (Halachmi et al., 2018).
Currently, there are two main approaches to silence lncRNA
expression, which are employed in pre-clinical models: the use
of RNAi-based methods, such as siRNA, and LNA-GapmeR
antisense oligonucleotides (ASOs), which induce RNase cleavage.
Generally, the RNAi approach, including siRNA and short
hairpin RNA (shRNA), which can be delivered via viral
vector, is used predominanly for lncRNA that are localised
in the cytoplasm. In particular, it has been demonstrated that
siRNA targeting cytoplasmic lncRNA SMILR can reduce SMILR
expression and attenuate pathological human saphenous vein
SMC proliferation (Ballantyne et al., 2016). On the other
hand, GapmeRs can be used for nuclear-localised lncRNA due
to the fact that it induces degradation by RNase-H and is
RISC-independent (Haemmig and Feinberg, 2017). Furthermore,
GapmeRs can be used to modulate lncRNA expression for in vivo.
In particular, intraperitoneal injection of GapmeRs in mice model
of hindlimb ischaemia was able to significantly reduce MALAT1
expression in the muscle tissue leading to poor blood flow
recovery and diminished capillary density (Michalik et al., 2014).
In another study, the GapmeR was used to inhibit the lncRNA
Chast, which is upregulated in hypertrophic heart tissue from
aortic stenosis patients. Notably, the in vivo delivery of GapmeR
targeting Chast resulted in decrease in pathological cardiac
remodelling with no side effects (Viereck et al., 2016). Finally,
CRISPR/Cas9 genome editing method is an attractive emerging
tool for modulation of gene expression including manipulation
of lncRNAs. To date, the CRISPR-inhibition (CRISPRi) approach
has been shown to knockdown the expression of six lncRNA
including GAS5, H19, MALAT1, NEAT1, TERC, and XIST
(Gilbert et al., 2014). Despite the fact that CRISPR/Cas9 method
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is at its nascent stages, coupled with viral-based delivery systems,
it holds much potential in terms of ncRNA-based therapeutics.
CONCLUSION
There remains little doubt that ncRNAs are important players
in the pathology of vascular disease, and have been repeatedly
demonstrated as key regulators of vascular biology in cell culture
models, animal models, and in human samples. Aggressive
lifestyle and risk factor management has had only a modest
incremental effect on the trajectory of atherosclerotic disease in
the last 70 years, even including the introduction of statins, and
the huge improvements in surgical and interventional medicine.
A new approach is now needed, and with the advent of CRISPR
technology and the ongoing advances in delivery by viral vectors,
non-coding gene therapy to up or downregulate culprit loci and
transcripts has become a reality. With ever deeper understanding
of molecular disease mechanisms and the refinement of safe and
efficacious delivery methods the targeting of miRNA and lncRNA
holds much promise for vascular disease treatment in future.
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